Ind-Swift Laboratories Submits SEBI Regulation 74(5) Certificate for Q2 FY26
Ind-Swift Laboratories submitted a certificate under SEBI Regulation 74(5) for the quarter ended 30th September, 2025, confirming dematerialization compliance.
This is a mandatory regulatory filing that confirms standard operational compliance and does not contain information likely to significantly influence investor decisions or the company's financial outlook.
The announcement is a standard compliance filing confirming adherence to SEBI regulations regarding share dematerialization, which has no direct positive or negative financial implications.
Ind-Swift Laboratories Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2025. * The certificate, dated 6th October, 2025, was received from Alankit Assignments Limited, the Company's Registrar and Transfer Agent. * It confirms that physical share certificates received for dematerialization of securities (Equity Shares) have been listed on the Stock Exchanges. * It also certifies that these certificates, after due verification, have been mutilated and cancelled, and the name of the depository has been substituted in the company's records as the registered owner.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.